Healthcare / BiotechnologyNasdaqGS
$4.75
-0.01 (-0.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-22.2M · quality 31.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-61.6%
↓Gross Margin
18.3%
↓Debt/Equity
1.72
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+4.4%
FCF CAGR
—
FCF margin
-38.1%
FCF / Net income
0.54x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $185.7M · net income $-130.8M · FCF $-70.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $185.7M | $185.7M | $259.2M | $288.9M | $883.0M | $799.2M | $284.1M | $143.1M |
| Net Income | $-130.8M | $-130.8M | $-144.8M | $-119.0M | $220.2M | $182.0M | $89.0M | $-4.5M |
| EBITDA | $-147.5M | $-147.5M | $-156.9M | $712.4M | $610.0M | — | — | — |
| EPS | — | — | -1.05 | -0.90 | 1.67 | 1.56 | 2.36 | -0.03 |
| Gross Margin | 18.3% | 18.3% | 41.8% | 48.5% | 80.9% | — | — | — |
| Operating Margin | -69.2% | -69.2% | -28.0% | -9.9% | 64.1% | 69.4% | 42.2% | 16.8% |
| Net Margin | -70.4% | -70.4% | -55.9% | -41.2% | 24.9% | 22.8% | 31.3% | -3.1% |
| Balance Sheet | ||||||||
| Debt/Equity | 1.72 | 1.72 | 1.16 | 1.47 | 1.07 | 1.66 | 5.97 | — |
| Current Ratio | 5.91 | 5.91 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-70.7M | $-70.7M | $-22.2M | $60.7M | $518.9M | $353.7M | $126.8M | $7.0M |
| Returns | ||||||||
| ROE | -61.6% | -61.6% | -44.5% | -28.6% | 40.4% | 57.7% | 100.5% | — |
| Valuation | ||||||||
| P/E | — | — | — | — | 7.89 | — | — | — |
| EV/EBITDA | — | — | — | 1.26 | 5.44 | — | — | — |
| P/B | 3.25 | 3.25 | 2.41 | 2.07 | 6.17 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | -28.3% | -28.3% | -10.3% | -67.3% | — | 181.3% | 98.5% | — |
| EPS Growth | — | — | -16.7% | -153.9% | — | -33.9% | 7966.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+122.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.05 → n/d
Residual
+122.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.